.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Chubb
Mallinckrodt
UBS
Deloitte
Boehringer Ingelheim
Healthtrust
Chinese Patent Office
Express Scripts
Moodys

Generated: December 18, 2017

DrugPatentWatch Database Preview

Claims for Patent: 8,637,540

« Back to Dashboard

Claims for Patent: 8,637,540

Title:Compositions for deterring abuse of opioid containing dosage forms
Abstract: This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.
Inventor(s): Kumar; Vijai (Morris Plains, NJ), Dixon; David (Woodside, NY), Tewari; Divya (West Chester, PA), Wadgaonkar; Dilip B. (Suffern, NY)
Assignee: Acura Pharmaceuticals (Chicago, IL)
Application Number:13/926,206
Patent Claims: 1. A therapeutic pharmaceutical composition comprising: a mixture including (a) an opioid; (b) a gel-forming polymer in an amount of about 3 to about 40 wt %; (c) a disintegrant; and (d) a surfactant; wherein the disintegrant is present in an amount sufficient to cause the pharmaceutical composition to exhibit an immediate release profile.

2. The therapeutic pharmaceutical composition of claim 1, wherein the pharmaceutical composition is in unit dose form.

3. The therapeutic pharmaceutical composition of claim 1, wherein the pharmaceutical composition is in suppository, capsule, caplet, pill, gel, soft gelatin capsule, or compressed tablet form.

4. The therapeutic pharmaceutical composition of claim 1, wherein the opioid susceptible to abuse is present in an amount of 0.5 to about 25 wt % of the composition.

5. The therapeutic pharmaceutical composition of claim 1, wherein the disintegrant is present in an amount of about 2 to about 25 wt % of the composition.

6. The therapeutic pharmaceutical composition of claim 1, wherein the surfactant is present in an amount of about 1 to about 10 wt % of the composition.

7. The therapeutic pharmaceutical composition of claim 1, wherein the disintegrant is selected from the group consisting of sodium starch glycolate, crospovidone, and croscarmellose sodium.

8. A therapeutic pharmaceutical composition comprising: a mixture including (a) an opioid selected from the group consisting of alfentanil, buprenorphine, butorphanol, carfentanil, codeine, dezocine, diacetylmorphine, dihydrocodeine, dihydromorphine, diprenorphine, etorphine, fentanyl, hydrocodone, hydromorphone, .beta.-hydroxy-3-methylfentanyl, levo-.alpha.-acetylmethadol, levorphanol, lofentanil, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, pethidine, propoxyphene, remifentanil, sufentanil, tilidine, tramadol, and pharmaceutically acceptable salts thereof; (b) a gel-forming polymer in an amount of about 3 to about 40 wt %; (c) a disintegrant; and (d) a surfactant; wherein the disintegrant is present in an amount sufficient to cause the pharmaceutical composition to exhibit an immediate release profile.

9. The therapeutic pharmaceutical composition of claim 8, wherein the pharmaceutical composition is in unit dose form.

10. The therapeutic pharmaceutical composition of claim 8, wherein the pharmaceutical composition is in suppository, capsule, caplet, pill, gel, soft gelatin capsule, or compressed tablet form.

11. The therapeutic pharmaceutical composition of claim 8, wherein the opioid is present in an amount of 0.5 to about 25 wt % of the composition.

12. The therapeutic pharmaceutical composition of claim 8, wherein the disintegrant is present in an amount of about 2 to about 25 wt % of the composition.

13. The therapeutic pharmaceutical composition of claim 8, wherein the surfactant is present in an amount of about 1 to about 10 wt % of the composition.

14. The therapeutic pharmaceutical composition of claim 8, wherein the disintegrant is selected from the group consisting of sodium starch glycolate, crospovidone, and croscarmellose sodium.

15. A therapeutic pharmaceutical composition comprising: a mixture including (a) oxycodone hydrochloride; (b) a gel-forming polymer in an amount of about 3 to about 40 wt %; (c) a disintegrant; and (d) a surfactant; wherein the disintegrant is present in an amount sufficient to cause the pharmaceutical composition to exhibit an immediate release profile.

16. The therapeutic pharmaceutical composition of claim 15, wherein the pharmaceutical composition is in unit dose form.

17. The therapeutic pharmaceutical composition of claim 15, wherein the pharmaceutical composition is in suppository, capsule, caplet, pill, gel, soft gelatin capsule, or compressed tablet form.

18. The therapeutic pharmaceutical composition of claim 15, wherein the oxycodone hydrochloride is present in an amount of 0.5 to about 25 wt % of the composition.

19. The therapeutic pharmaceutical composition of claim 15, wherein the disintegrant is present in an amount of about 2 to about 25 wt % of the composition.

20. The therapeutic pharmaceutical composition of claim 15, wherein the surfactant is present in an amount of about 1 to about 10 wt % of the composition.

21. The therapeutic pharmaceutical composition of claim 15, wherein the disintegrant is selected from the group consisting of sodium starch glycolate, crospovidone, and croscarmellose sodium.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Cerilliant
Cantor Fitzgerald
QuintilesIMS
Chinese Patent Office
Harvard Business School
Daiichi Sankyo
McKinsey
Farmers Insurance
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot